1. PTEN‐knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid
   Lujing Wang et al, 2022, The FASEB Journal CrossRef
2. EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway
   Xinyue Zhao et al, 2022, Journal of Oncology CrossRef
3. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high‐grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study
   Margaret E. Macy et al, 2017, Pediatric Blood & Cancer CrossRef
4. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
   Ahmed F. Salem et al, 2020, Cancers CrossRef
5. EphA2 signaling within integrin adhesions regulates fibrillar adhesion elongation and fibronectin deposition
   Alexandra C Finney et al, 2021, Matrix Biology CrossRef
6. Nanomedicine for the Treatment of Advanced Prostate Cancer
   Sonia Vicente‐Ruiz et al, 2021, Advanced Therapeutics CrossRef
7. A Hoechst Reporter Enables Visualization of Drug Engagement In Vitro and In Vivo: Toward Safe and Effective Nanodrug Delivery
   Takuya Miyazaki et al, 2022, ACS Nano CrossRef
8. EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis
   Alexandra C. Finney et al, 2017, Circulation CrossRef
9. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer
   Ashwin Sachdeva et al, 2022, British Journal of Cancer CrossRef
10. Tumor microenvironment complexity and therapeutic implications at a glance
    Roghayyeh Baghban et al, 2020, Cell Communication and Signaling CrossRef
11. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo
    Amanda K. Pearce et al, 2016, Pharmaceutical Research CrossRef
12. Precision nanomedicines for prostate cancer
    Anna Cifuentes-Rius et al, 2018, Nanomedicine CrossRef
13. Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells
    Deok-Soo Han et al, 2022, Scientific Reports CrossRef
14. Serum promotes vasculogenic mimicry through the EphA2/VE-cadherin/AKT pathway in PC-3 human prostate cancer cells
    Changhwan Yeo et al, 2019, Life Sciences CrossRef
15. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids
    Ezgi Oner et al, 2021, Journal of Nanobiotechnology CrossRef
16. Nanoparticles and phototherapy combination as therapeutic alternative in prostate cancer: A scoping review
    Liah Aira Dias Ferreira et al, 2023, European Journal of Pharmacology CrossRef
17. Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation
    Yun Xiang et al, 2019, Biomedicine & Pharmacotherapy CrossRef
18. EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10
    Yingjing Wang et al, 2019, Journal of Cellular Physiology CrossRef
19. Differential expression of EphA5 protein in gastric carcinoma and its clinical significance
    Wei Zhang et al, 2019, Oncology Letters CrossRef